Independent review discusses evidence supporting the use of betahistine to alleviate residual dizziness following physical repositioning procedures in benign paroxysmal positional vertigo (BPPV) ...
Altamira intends to partner or divest AM-125 as part of its legacy assets in a strategic pivot to its RNA delivery technology platforms HAMILTON, BERMUDA / ACCESSWIRE / April 10, 2023 / Altamira ...
HAMILTON, BERMUDA / ACCESSWIRE / June 15, 2023 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet ...
HAMILTON, Bermuda - Altamira Therapeutics Ltd. (NASDAQ:CYTO), a biopharmaceutical company, has drawn attention to a peer-reviewed article that endorses the use of betahistine for treating residual ...
Betahistine (Betahist Forte (16mg)) is an anti-vertigo agent, prescribed for dizziness (vertigo) in those who have Meniere's disease.It causes vasodilatation in inner ear. The information provided on ...
Benign paroxysmal positional vertigo, or BPPV, is a common cause of vertigo. BPPV occurs when crystals move from one part of the inner ear to another, disrupting signals to the brain. When a person ...
Review the side-effects of Betahistine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
HAMILTON, BERMUDA / ACCESSWIRE / April 10, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results